Skip to main content
IMRX
NASDAQ Life Sciences

Atebimetinib Data Show Weight Preservation Doubles Survival in Pancreatic Cancer

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$4.36
Mkt Cap
$276.258M
52W Low
$3.86
52W High
$9.6
52W Position info
13% above low
Off High info
55% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

IMRX is trading near its 52-week low of $3.86 (13% above the low).

Summary

Immuneering presented new Phase 2a analyses at AACR 2026 showing atebimetinib + mGnP patients were twice as likely to maintain or gain weight versus a benchmark, and weight-stable patients had significantly longer overall survival (HR=3.13, p=0.049). The data also suggest tumor reduction presence, not depth, drives survival benefit. This supports the dual mechanism (tumor shrinkage + cachexia counteraction) behind the 17.3-month median OS reported at ASCO 2026. The ongoing Phase 3 MAPKeeper 301 trial is actively enrolling first-line pancreatic cancer patients, making this a key validation readout for the registrational program.

At the time of this announcement, IMRX was trading at $4.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $276.3M. The 52-week trading range was $3.86 to $9.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

IMRX - Latest Insights

IMRX
Oct 29, 2026, 4:12 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.02
Real-time Price: $3.46 info
Change: -$0.560 (-14%) info
Market Cap: $226.671M info
IMRX
Oct 29, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.02
Real-time Price: $3.46 info
Change: -$0.560 (-14%) info
Market Cap: $226.671M info
IMRX
Aug 05, 2026, 7:41 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.23
Real-time Price: $3.46 info
Change: -$0.770 (-18%) info
Market Cap: $226.671M info
IMRX
Jul 21, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $4.51
Real-time Price: $3.46 info
Change: -$1.05 (-23%) info
Market Cap: $226.671M info
IMRX
Jun 15, 2026, 4:12 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.19
Real-time Price: $3.46 info
Change: -$0.730 (-17%) info
Market Cap: $226.671M info